Atrial Cardiomyopathy: A Cardiologist’s Guide to Stroke, Heart Failure, and Arrhythmias

Atrial cardiomyopathy has emerged as a comprehensive pathophysiological construct encompassing structural, architectural, contractile, and electrophysiological abnormalities of the atrial myocardium. Traditionally, atrial fibrillation (AF) has been regarded as the primary manifestation of atrial disease; however, accumulating evidence suggests that atrial cardiomyopathy often precedes AF and independently contributes to adverse cardiovascular outcomes, including ischemic stroke, heart failure with preserved ejection fraction, and a spectrum of atrial arrhythmias. This paradigm shift has significant clinical and research implications. Atrial fibrosis, inflammation, oxidative stress, and endothelial dysfunction collectively drive atrial remodeling, which impairs atrial reservoir and booster pump function while promoting thrombogenesis even in the absence of overt AF. Advanced imaging modalities, including speckle-tracking echocardiography and cardiac magnetic resonance imaging (CMR), coupled with emerging biomarkers, have enabled earlier detection, phenotyping, and risk stratification of atrial disease. Furthermore, the recognition of atrial cardiomyopathy challenges the current AF-centric approach to anticoagulation, rhythm management, and preventive cardiology. This narrative review synthesizes current evidence on the pathophysiology, diagnostic strategies, clinical consequences, and therapeutic implications of atrial cardiomyopathy. Emphasis is placed on its role as a unifying substrate for stroke, heart failure, and arrhythmias, as well as on potential strategies for early identification and precision-based interventions. Understanding atrial cardiomyopathy as a distinct disease entity has the potential to transform clinical practice, optimize patient outcomes, and guide future research directions in cardiovascular medicine.